摘要
目的探讨紫杉醇脂质体与传统紫杉醇联合顺铂治疗晚期食管癌的疗效和安全性。方法 62例经病理组织学确诊的晚期食管癌患者随机分为2组,紫杉醇脂质体组(32例):采用紫杉醇脂质体135mg.m-2,d1;紫杉醇组(30例):采用传统紫杉醇135 mg.m-2,d1,2组均联合应用顺铂30 mg.m-2,d1～3,2周期后评价疗效及安全性。结果 2组有效率比较差异无统计学意义(P>0.05),恶心呕吐、肌肉关节痛的发生率紫杉醇脂质体组明显低于传统紫杉醇组(P<0.05)。结论紫杉醇脂质体联合顺铂与传统紫杉醇联合顺铂治疗晚期食管癌近期疗效相当,但毒副反应明显降低。
Objective To compare the efficacy and safety of paclitaxel liposome and paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer. Methods Sixty-two patients with advanced esophageal cancer were divided into the paclitaxel liposome group （32 patients） and the paclitaxel group （30 patients）. The dose of paclitaxel liposome or paclitaxel was 135 mg ·m^-2 on d1 ,all the patients received cisplatin at a dose of 30 -2 m·m^-2on d1-3 ,the efficacy and safety were evaluated after two cycles. Results There was no significant difference in the overall response rate between the two groups （P 〉 0.05）. There were significant differences in nausea and vomiting, muscle and joint pain between the two groups （ P 〈 0.05 ）. Conclusion Paclitaxel liposome is as effective as paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer, and the toxicities of paclitaxel liposome are less than paclitaxel.
出处
《肿瘤基础与临床》
2013年第4期301-303,共3页
journal of basic and clinical oncology
关键词
紫杉醇脂质体
紫杉醇
顺铂
食管癌
paclitaxel liposome
paclitaxel
cisplatin
esophageal cancer
